0001209191-20-007495.txt : 20200207
0001209191-20-007495.hdr.sgml : 20200207
20200207161628
ACCESSION NUMBER: 0001209191-20-007495
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200205
FILED AS OF DATE: 20200207
DATE AS OF CHANGE: 20200207
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LEIDEN JEFFREY M
CENTRAL INDEX KEY: 0001242825
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 20587638
MAIL ADDRESS:
STREET 1: 40 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-02-05
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001242825
LEIDEN JEFFREY M
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
1
1
0
0
CEO & President
Common Stock
2019-02-05
4
A
0
50566
0.00
A
156912
D
Common Stock
2019-02-05
4
A
0
28444
0.00
A
185356
D
Common Stock
2019-02-05
4
A
0
31462
0.00
A
216818
D
Common Stock
440
I
401(k)
Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2017 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020 and the shares will vest on 02/10/2020.
Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020 and the shares will vest in installments beginning on 02/24/2020.
Restricted stock unit award that will vest pursuant to his employment agreement upon Dr. Leiden's transition from CEO.
/s/ Omar White, Attorney-in-Fact
2020-02-07